Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.78 |
| ▸ | CA12 | O43570 | 6/20 | 0.72 |
| ▸ | CA2 | P00918 | 6/20 | 0.72 |
| ▸ | CA9 | Q16790 | 5/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | MPO | P05164 | 7/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL460754 | 0.88 | TSHR (1.00) | TSHRCYP2D6HIF1ACA12CA2 | |
| SCHEMBL1238295 | 0.85 | CA12 (0.77) | TSHRCYP2D6HIF1ACA12CA2 | |
| SCHEMBL2794849 | 0.84 | CA12 (1.00) | TSHRCYP2D6HIF1ACA12CA2 | |
| SCHEMBL31532322 | 0.84 | CA12 (1.00) | TSHRCYP2D6HIF1ACA12CA2 | |
| SCHEMBL12083246 | 0.84 | TSHR (0.82) | TSHRCYP2D6HIF1ACA12CA2 | |
| Hydrochloric Acid SCHEMBL1238093 | 0.84 | CA12 (0.74) | TSHRCYP2D6HIF1ACA12CA2 | |
| SCHEMBL13973324 | 0.83 | TSHR (0.54) | TSHRCYP2D6HIF1ACA12CA2 | |
| SCHEMBL20535946 | 0.82 | CA12 (0.79) | TSHRCYP2D6HIF1ACA12CA2 | |
| SCHEMBL30586214 | 0.82 | CA12 (0.95) | TSHRCYP2D6HIF1ACA12CA2 | |
| SCHEMBL30586211 | 0.82 | CA12 (0.95) | TSHRCYP2D6HIF1ACA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083686-A1 | METHODS FOR SUPPRESSING ACCUMULATION OF REFLUX-INDUCED PROTEIN ADDUCTS | UNIV VANDERBILT (US) | 2026-03-26 | — | — | US | claimed |
| US-20250381155-A1 | USE OF 2-HYDROXYBENZYLAMINE IN THE TREATMENT AND PREVENTION OF PULMONARY HYPERTENSION | UNIV VANDERBILT (US) | 2025-12-18 | — | — | US | claimed |
| US-12383515-B2 | Compositions and methods of use of γ-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver | MTI BIOTECH, INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-20250214939-A1 | METHOD FOR TREATING INFLAMMATION AND HYPERTENSION WITH GAMMA-KETOALDEHYDE SKAVENGERS | VANDERBILT UNIVERSITY | 2025-07-03 | — | — | US | claimed |
| CN-119212681-A | Method for preparing 3-D printed pharmaceutical products | 百时美施贵宝公司 | 2024-12-27 | — | — | CN | claimed |
| CN-118290290-A | Preparation method and application of continuous flow for synthesizing ethylsalicylamine | 天津大学 | 2024-07-05 | — | — | CN | claimed |
| US-20240189291-A1 | Prevention And Treatment Of Atrial Fibrillation/Flutter With Gamma-Ketoaldehyde Scavengers | VANDERBILT UNIVERSITY | 2024-06-13 | — | — | US | claimed |
| CN-117597115-A | Coated solid pharmaceutical preparation | SS制药株式会社 | 2024-02-23 | — | — | CN | claimed |
| US-20240000726-A1 | COMPOUNDS AND METHODS FOR SCAVENGING DICARBONYL ELECTROPHILES | VANDERBILT UNIVERSITY | 2024-01-04 | — | — | US | claimed |
| US-20230364032-A1 | USE OF 2-HOBA TO TREAT ATHEROSCLEROSIS | VANDERBILT UNIVERSITY | 2023-11-16 | — | — | US | claimed |
| EP-4157243-A1 | USE OF 2-HOBA TO TREAT ATHEROSCLEROSIS | Vanderbilt University (US) | 2023-04-05 | — | — | EP | claimed |
| CN-115607556-A | Medicine for preventing and treating asthma, chronic obstructive pulmonary disease, allergic diseases, etc | 刘力 | 2023-01-17 | — | — | CN | claimed |
| US-11400103-B2 | Methods of preventing platelet activation | VANDERBILT UNIVERSITY (US) | 2022-08-02 | — | — | US | claimed |
| US-11389414-B2 | Methods for treating atherosclerosis with gamma-ketoaldehyde scavengers | VANDERBILT UNIVERSITY (US) | 2022-07-19 | — | — | US | claimed |
| WO-2022081777-A1 | METHOD OF PREVENTING KIDNEY INJURY DISRUPTION OF INTESTINAL LYMPHATICS | VANDERBILT UNIVERSITY (US) | 2022-04-21 | — | — | WO | claimed |
| US-20200383938-A1 | COMPOUNDS AND METHODS FOR SCAVENGING DICARBONYL ELECTROPHILES | VANDERBILT UNIVERSITY | 2020-12-10 | — | — | US | claimed |
| US-20200246358-A1 | METHODS OF PREVENTING PLATELET ACTIVATION | VANDERBILT UNIVERSITY | 2020-08-06 | — | — | US | claimed |
| US-20200197323-A1 | METHODS FOR SUPPRESSING ACCUMULATION OF REFLUX-INDUCED PROTEIN ADDUCTS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2020-06-25 | — | — | US | claimed |
| US-20200138747-A1 | METHODS FOR TREATING ATHEROSCLEROSIS WITH GAMMA-KETOALDEHYDE SCAVENGERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-05-07 | — | — | US | claimed |
| WO-1992017559-A1 | STABILIZED DICHLOROTRIFLUOROETHANE REFRIGERATION COMPOSITIONS | ALLIED-SIGNAL INC. (US) | 1992-10-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000726-A1 | COMPOUNDS AND METHODS FOR SCAVENGING DICARBONYL ELECTROPHILES | OGG1, LGMN, GLO1 | TSHR 4757/4885CYP2D6 1105/4885HIF1A 1438/4885 |
| US-20200383938-A1 | COMPOUNDS AND METHODS FOR SCAVENGING DICARBONYL ELECTROPHILES | OGG1, LGMN, GLO1 | TSHR 4757/4885CYP2D6 1105/4885HIF1A 1438/4885 |
| US-20240189291-A1 | Prevention And Treatment Of Atrial Fibrillation/Flutter With Gamma-Ketoaldehyde Scavengers | KCNH1, AKR7A2, GLO1 | TSHR 1933/4885CYP2D6 1287/4885HIF1A 636/4885 |
| US-12383515-B2 | Compositions and methods of use of γ-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver | AKR7A2, CPT1A, FABP1 | TSHR 4558/4885CYP2D6 2183/4885HIF1A 805/4885 |
| US-20260083686-A1 | METHODS FOR SUPPRESSING ACCUMULATION OF REFLUX-INDUCED PROTEIN ADDUCTS | FABP2, DNAJC10, FABP6 | TSHR 1044/4885CYP2D6 1469/4885HIF1A 4176/4885 |
| US-11389414-B2 | Methods for treating atherosclerosis with gamma-ketoaldehyde scavengers | HMGCR, CTH, GSTK1 | TSHR 4661/4885CYP2D6 4278/4885HIF1A 143/4885 |
| US-20200197323-A1 | METHODS FOR SUPPRESSING ACCUMULATION OF REFLUX-INDUCED PROTEIN ADDUCTS | FABP2, HSPBP1, FABP6 | TSHR 3195/4885CYP2D6 1859/4885HIF1A 3784/4885 |
| US-20230364032-A1 | USE OF 2-HOBA TO TREAT ATHEROSCLEROSIS | HACL2, APOB, OAT | TSHR 3707/4885CYP2D6 4024/4885HIF1A 855/4885 |
| US-20250214939-A1 | METHOD FOR TREATING INFLAMMATION AND HYPERTENSION WITH GAMMA-KETOALDEHYDE SKAVENGERS | NFKBIA, PTGS1, HMGCR | TSHR 3379/4885CYP2D6 3741/4885HIF1A 52/4885 |
| US-20200138747-A1 | METHODS FOR TREATING ATHEROSCLEROSIS WITH GAMMA-KETOALDEHYDE SCAVENGERS | HMGCR, CTH, GSTK1 | TSHR 4661/4885CYP2D6 4278/4885HIF1A 143/4885 |
| US-20250381155-A1 | USE OF 2-HYDROXYBENZYLAMINE IN THE TREATMENT AND PREVENTION OF PULMONARY HYPERTENSION | SIRT3, SIRT2, GLS | TSHR 4361/4885CYP2D6 1648/4885HIF1A 155/4885 |
| US-20200246358-A1 | METHODS OF PREVENTING PLATELET ACTIVATION | PLG, PLA2G7, PLAT | TSHR 4133/4885CYP2D6 3358/4885HIF1A 1538/4885 |
| US-11400103-B2 | Methods of preventing platelet activation | PLG, PLA2G7, PLAT | TSHR 4133/4885CYP2D6 3358/4885HIF1A 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.